InspireMD (NSPR) 10-K 30 Mar 23 2022 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 28, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-35731
Entity Registrant Name	InspireMD, Inc.
Entity Central Index Key	0001433607
Entity Tax Identification Number	26-2123838
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	4 Menorat Hamaor St.
Entity Address, City or Town	Tel Aviv
Entity Address, Country	IL
Entity Address, Postal Zip Code	6744832
City Area Code	(888)
Local Phone Number	776-6804
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	NSPR
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 15,650,407
Entity Common Stock, Shares Outstanding		8,326,648
Documents Incorporated By Reference	None
ICFR Auditor Attestation Flag	false
Auditor Firm ID	1309
Auditor Name	Kesselman&Kesselman
Auditor Location	Tel-Aviv, Israel

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands		Dec. 31, 2022	Dec. 31, 2021
CURRENT ASSETS:
Cash and cash equivalents		$ 4,632	$ 12,004
Short-term bank deposits		13,171	22,036
Accounts receivable:
Trade, net		1,034	1,224
Other		213	165
Prepaid expenses		655	522
Inventory		1,621	1,143
TOTAL CURRENT ASSETS		21,326	37,094
NON-CURRENT ASSETS:
Property, plant and equipment, net		917	632
Operating lease right of use assets		1,554	1,081
Fund in respect of employee rights upon retirement		856	905
TOTAL NON-CURRENT ASSETS		3,327	2,618
TOTAL ASSETS		24,653	39,712
Accounts payable and accruals:
Trade		659	893
Other		4,411	3,454
TOTAL CURRENT LIABILITIES		5,070	4,347
LONG-TERM LIABILITIES:
Operating lease liabilities		1,195	781
Liability for employee rights upon retirement		995	1,052
TOTAL LONG-TERM LIABILITIES		2,190	1,833
COMMITMENTS AND CONTINGENT LIABILITIES (Note 6)
TOTAL LIABILITIES		7,260	6,180
EQUITY:
Common stock, par value $0.0001 per share; 150,000,000 shares authorized at December 31, 2022 and 2021; 8,330,918 and 8,296,256 shares issued and outstanding at December 31, 2022 and 2021, respectively		1	1
Preferred C shares, par value $0.0001 per share; 1,172,000 shares authorized at December 31, 2022 and 2021; 1,718 shares issued and outstanding at December 31, 2022 and 2021;	[1]
Additional paid-in capital		218,977	216,625
Accumulated deficit		(201,585)	(183,094)
Total equity		17,393	33,532
Total liabilities and equity		$ 24,653	$ 39,712
[1]Represents an amount less than $1

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	8,330,918	8,296,256
Common stock, shares outstanding	8,330,918	8,296,256
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,172,000	1,172,000
Preferred stock, shares issued	1,718	1,718
Preferred stock, shares outstanding	1,718	1,718

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
REVENUES	$ 5,171	$ 4,495
COST OF REVENUES	4,054	3,741
GROSS PROFIT	1,117	754
OPERATING EXPENSES:
Research and development	7,810	5,158
Selling and marketing	3,664	2,907
General and administrative	8,356	7,405
Total operating expenses	19,830	15,470
LOSS FROM OPERATIONS	(18,713)	(14,716)
FINANCIAL INCOME (EXPENSES), net:	250	(157)
LOSS BEFORE TAX EXPENSES	(18,463)	(14,873)
TAX EXPENSES	28	45
NET LOSS	$ (18,491)	$ (14,918)
NET LOSS PER SHARE - basic and diluted	$ (2.35)	$ (2.03)
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES USED IN COMPUTING NET LOSS PER SHARE - basic and diluted	7,871,814	7,346,022

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands		Common Stock [Member]		Preferred Stock [Member] Series B Convertible Preferred Stock [Member]		Preferred Stock [Member] Series C Convertible Preferred Stock [Member]		Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020			[1]		[1]		[1]	$ 180,339	$ (168,176)	$ 12,163
Beginning balance, shares at Dec. 31, 2020		3,284,322		17,303		2,343
Net loss									(14,918)	(14,918)
Issuance of common shares, including at the market offering net of $2,024 issuance costs		$ 1						25,241		25,242
Issuance of common shares, including at the market offering net of $2,024 issuance costs, shares		3,133,775
Exercise of Warrants F			[1]					8,120		8,120
Exercise of Warrants F, shares		1,093,536
Exercise of Warrants G			[1]					1,349		1,349
Exercise of Warrants G, shares		131,876
Conversion of Series B Convertible Preferred Stock to common shares	[1]
Conversion of series B convertible preferred stock to common shares, shares		207,528		(17,303)
Conversion of Series C Convertible Preferred Stock to common shares	[1]
Conversion of series C convertible preferred stock to common shares, shares		831				(625)
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of shares								1,576		1,576
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures, shares		399,120
Round up of shares due to reverse stock split effectuated on April 26, 2021			[1]								[1]
Round up of shares due to reverse stock split effectuated on April 26, 2021, shares		45,268
Ending balance, value at Dec. 31, 2021		$ 1					[1]	216,625	(183,094)	33,532
Ending balance, shares at Dec. 31, 2021		8,296,256				1,718
Net loss									(18,491)	(18,491)
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of shares								2,352		2,352
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures, shares		34,662
Ending balance, value at Dec. 31, 2022		$ 1						$ 218,977	$ (201,585)	$ 17,393
Ending balance, shares at Dec. 31, 2022		8,330,918				1,718
[1]Represents an amount less than $1

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Equity (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Statement of Stockholders' Equity [Abstract]
Payments of stock issuance costs		$ 2,024
Shares, restricted stock award, forfeited	10,832	20,822

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (18,491,000)	$ (14,918,000)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	188,000	161,000
Gain from sale of property, plant and equipment		(1,000)
Change in liability for employees rights upon retirement	(57,000)	142,000
Other financial expense	131,000	8,000
Change in operating right of use asset and operating leasing liability	(60,000)	(14,000)
Increase in interest receivable on short term deposits	(135,000)	(36,000)
Share-based compensation expenses	2,352,000	1,576,000
Loss (gain) on amounts funded in respect of employee rights upon retirement, net	135,000	(67,000)
Changes in operating asset and liability items:
Decrease (Increase) in prepaid expenses	7,000	(188,000)
Decrease (increase) in trade receivables	190,000	(748,000)
Increase in other receivables	(48,000)	(19,000)
Decrease (increase) in inventory	(478,000)	272,000
Increase (decrease) in trade payables	(234,000)	657,000
Increase (decrease) in other payables	958,000	(35,000)
Net cash used in operating activities	(15,542,000)	(13,210,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment	(473,000)	(344,000)
Investment in short-term bank deposits	(19,000,000)	(24,000,000)
Withdrawal from short-term bank deposits	28,000,000	2,000,000
Amounts funded in respect of employee rights upon retirement	(86,000)	(113,000)
Net cash provided by (used in) investing activities	8,441,000	(22,457,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance costs of At The Market offering	(140,000)
Proceeds from issuance of shares and warrants and exercise of Pre-Funded Warrants and unit purchase option, net of $2,024 issuance costs		35,034,000
Net cash provided by (used in) financing activities	(140,000)	35,034,000
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	(131,000)	(8,000)
DECREASE IN CASH AND CASH EQUIVALENTS	(7,372,000)	(641,000)
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	12,004,000	12,645,000
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR	4,632,000	12,004,000
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Acquisition of right-of-use assets by means of lease liabilities	$ 835,000	$ 91,000

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
PreFunded Warrants and Unit Purchase Option [Member]
Payments of stock issuance costs	$ 2,024

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1 - DESCRIPTION OF BUSINESS a. General InspireMD, Inc., a Delaware corporation (the “Company”), together with its subsidiaries, is a medical device Company focusing on the development and commercialization of its proprietary MicroNet™ stent platform technology for the treatment of complex vascular and coronary disease. MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. The Company’s carotid product (CGuard™ EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease. The Company’s MGuard™ Prime™ embolic protection system (“MGuard Prime EPS”) was marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions, or bypass surgery. MGuard Prime EPS combines MicroNet with a bare-metal cobalt-chromium based stent. MGuard Prime EPS received CE mark approval in the European Union in October 2010 for improving luminal diameter and providing embolic protection. Over the past years, there has been a shift in industry preferences away from bare-metal stents, such as MGuard Prime EPS in ST-Elevation Myocardial Infarction (“STEMI”) patients. As a result of declining sales of the MGuard Prime EPS, which the Company believes is largely driven by the predominant industry preferences favoring drug-eluting, or drug-coated, stents, during the second quarter of 2022, the Company ceased sales of the Company’s MGuard Prime EPS following a phase out period. The Company markets its products through distributors in international markets, mainly in Europe. b. Liquidity The Company has an accumulated deficit as of December 31, 2022, as well as a history of net losses and negative operating cash flows in recent years. The Company expects to continue incurring losses and negative cash flows from operations until its product, CGuard™ EPS, reaches commercial profitability. As a result of these expected losses and negative cash flows from operations, along with the Company’s current cash position, the Company has sufficient resources to fund operations until the end of September 2023. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern. These financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. Management’s plans include the continued commercialization of the Company’s product and raising capital through the sale of additional equity securities, debt or capital inflows from strategic partnerships. There are no assurances however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in commercializing its products and raising capital, it may need to reduce activities, curtail or cease operations. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 1 - DESCRIPTION OF BUSINESS c. Failure to satisfy regulatory requirements of the new European Medical Device Regulation could prevent the Company from marketing CGuard EPS in countries requiring the CE Mark. For the European Union nations, medical devices must obtain a CE mark before they may be placed on the market. In order to obtain and maintain the CE mark, the Company must comply with EU law on medical devices, which, until May 26, 2021 was governed by the Medical Device Directive 93/42/EEC (“MDD”), by presenting comprehensive technical files for its products demonstrating safety and efficacy of the product to be placed on the market and passing initial and annual quality management system audit as per ISO 13485 standard by a European Notified Body. The Company has obtained ISO 13485 quality system certification and CGuard EPS that the Company currently distributes into the European Union, displays the required CE mark. In order to maintain certification, the Company is required to pass an annual surveillance audit conducted by Notified Body auditors. The European Union replaced the MDD with the new European Medical Device Regulation, or MDR (MDR 2017/745). The MDR entered into force after a transitional period of three years and a one year extension of that transition period due to the COVID-19 pandemic on May 26, 2021 and which changes several aspects of the regulatory framework in the European Union. Manufacturers had the duration of the transition period to update their technical documentation and processes to meet the new requirements in order to obtain a CE Mark. In the Company’s specific case, the Company’s’ CE mark for CGuard EPS under the MDD expired on November 12, 2022 and it is in the final stages of technical documentation review by the Notified Body auditor to meet the Medical Device Regulation (“MDR”) (MDR 2017/745) requirements (which replaced the MDD) for recertification. In the meantime, on February 14, 2023, the Company received a derogation per Article 97 paragraph 1 of Regulation 2017/745 from the Agency for Medicines and Health Products (FAMHP) allowing it to continue marketing CGuard EPS in the European Union until August 15, 2023 subject to certain procedural requirements. Subsequently, on March 20, 2023, Regulation (EU) 2023/607 was published allowing us to continue marketing CGuard EPS in EU countries under the MDD directive until December 31, 2027. This allows the Company to market and sell CGuard EPS in the EU and certain other jurisdictions subject to certain procedural requirements while the Company’s MDR CE recertification is pending. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 1 - DESCRIPTION OF BUSINESS d. Risks Related to the Geopolitical and Military Tensions Between Russia and Ukraine in Europe In February 2022, Russia launched a military invasion into Ukraine. The Company derived approximately 9.9% of total sales in Russia and Belarus in 2021 while during 2022 the Company’s sales to Russia and Belarus were 12.1%. The escalation of geopolitical instability in Russia and Ukraine as well as currency fluctuations in the Russian Ruble could negatively impact the Company’s operations, sales, and future growth prospects in that region. As a result of the crisis in Ukraine, the United States and the EU have implemented sanctions against certain Russian individuals and entities and have made it more difficult for us to collect on outstanding accounts receivable from customers in this region. The Company’s global operations expose the Company to risks that could adversely affect the Company’s business, financial condition, results of operations, cash flows or the market price of the Company’s securities, including the potential for increased tensions between the United States and Russia resulting from the current situation involving Russia and Ukraine, tariffs, economic sanctions and import-export restrictions imposed by either nation, and retaliatory actions by the other nation, as well as the potential negative impact on the Company’s business and sales in Russia, and Belarus. Current geopolitical instability in Russia and Ukraine and related sanctions by the U.S. government against certain companies and individuals may hinder the Company’s ability to conduct business with potential or existing customers and vendors in these countries. The U.S. government has imposed sanctions through several executive orders restricting U.S. companies from conducting business with specified Russian individuals and companies. While the Company believes that the executive orders currently do not preclude the Company from conducting business with the Company’s current customers or vendors in Russia, and Belarus, the sanctions imposed by the U.S. government may be expanded in the future to restrict the Company from engaging with them. If the Company is unable to conduct business with new or existing customers or vendors or pursue business opportunities in Russia, or Belarus, the Company’s business, including revenue, profitability and cash flows, and operations could be adversely affected. The Company cannot provide assurance that current sanctions or potential future changes in sanctions will not have a material impact on the Company’s operations in Russia, and Belarus or on the Company’s financial results. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES a. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory valuations and assessing the likelihood of exercise of options to extend the lease term. b. Functional currency The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). Accordingly, the functional currency of the Company and its subsidiaries is the U.S. dollar. The dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented in their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. The resulting translation gains or losses are recorded as financial income or expense, as appropriate. For transactions reflected in the statements of operations in foreign currencies, the exchange rates at transaction dates are used. Depreciation and changes in inventories and other changes deriving from non-monetary items are based on historical exchange rates. c. Principles of consolidation The consolidated financial statements include the accounts of the Company and of its subsidiaries. Intercompany transactions and balances have been eliminated upon consolidation. d. Cash and cash equivalents The Company considers all highly liquid investments, which include short-term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawal or use, to be cash equivalents. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES e. Short-term bank deposits Bank deposits with original maturities of more than three months but less than one year are presented as part of short-term bank deposits. Deposits are presented at their cost which approximates market values including accrued interest. Interest on deposits is recorded as financial income. f. Concentration of credit risk and allowance for doubtful accounts Financial instruments that may potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and short-term bank deposits, which are deposited in major financially sound institutions in the U.S, Israel and Germany, and trade accounts receivable. The Company’s trade accounts receivable is derived from revenues earned from customers from various countries. The Company performs ongoing credit evaluations of its customers’ financial condition and, requires no collateral from its customers. The Company also has a credit insurance policy for some of its customers. The Company maintains an allowance for doubtful accounts receivable based upon the expected ability to collect the accounts receivable. The Company reviews its allowance for doubtful accounts quarterly by assessing individual accounts receivable and all other balances based on historical collection experience and an economic risk assessment. If the Company determines that a specific customer is unable to meet its financial obligations to the Company, the Company provides an allowance for credit losses to reduce the receivable to the amount management reasonably believes will be collected, which is netted against “Accounts receivable - Trade”. g. Inventory Inventories are stated at the lower of cost (cost is determined on a “first-in, first-out” basis) or net realizable value. The Company’s inventories generally have a limited shelf life and are subject to impairment as they approach their expiration dates. The Company regularly evaluates the carrying value of its inventory and when, based on such evaluation, factors indicate that impairment has occurred, the Company impairs the inventories’ carrying value. h. Leases Operating leases are included in operating lease right-of-use (“ROU”) assets. Short-term balances regarding lease liabilities are included in accounts payable and accruals - Other and long-term balances regarding lease liabilities are included in operating lease liabilities. ROU assets represent Company’s right to use an underlying asset for the lease term and lease liabilities represent obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses the incremental borrowing rate based on the information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The determination of the incremental borrowing rate requires management judgment based on information available at lease commencement. The lease terms may include periods covered by options to extend the lease when it is reasonably certain that the Company will exercise such options, and periods covered by options to terminate the lease when it is reasonably certain that the Company will not exercise such options. Operating lease cost is recognized on a straight-line basis over the lease term. Lease agreements that include lease and non-lease components are accounted for as a single lease component. The Company elected the short-term lease recognition exemption for leases with a lease term of 12 months or less. i. Property, plant and equipment Property, plant and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets: over three years for computers and other electronic equipment, and seven to fifteen years for office furniture and equipment and machinery and equipment (mainly seven years ). Leasehold improvements are amortized on a straight-line basis over the term of the lease, which is shorter than the estimated life of the improvements. j. Impairment in value of long-lived assets The Company tests long-lived tangible assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment would be recognized, and the assets would be written down to their estimated fair values, based on expected future discounted cash flows. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES k. Revenue recognition A contract with a customer exists only when: 1) the parties to the contract have approved it and are committed to perform their respective obligations, 2) the Company can identify each party’s rights regarding the distinct goods or services to be transferred (“Performance Obligations”), 3) the Company can determine the transaction price for the goods or services to be transferred, 4) the contract has commercial substance and 5) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for Performance Obligations upon transfer of control to the customer, excluding sales taxes. Revenue from sales of goods, including sales to distributors, is recognized when the customer obtains control of the product, once the Company has a present right to payment and the customer has legal title, and risk and rewards of ownership are obtained by the customer. Generally, this occurs when products are shipped. In few cases when products are directly sold to medical centers on consignment basis, revenue is recognized when the product is consumed. The Company recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under selling and marketing expenses. Disaggregated revenue is disclosed in Note 11. The Company recognizes revenue net of value added tax (VAT). l. Research and development costs Research and development costs, including the costs of the Company’s US based clinical trial costs of approximately $4,468,000 2,037,000 m. Share-based compensation The Company has equity incentive plans under which the Company grants equity awards, including stock options, restricted stock and restricted stock units (“RSUs”) to employees and service providers. Employee equity awards are classified as equity awards and accounted for using the grant-date fair value method. The Company determines compensation expense associated with restricted stock and RSUs based on the fair value of our common stock on the date of grant. The fair value of option awards is estimated using the Black-Scholes valuation model and expensed over the requisite service period. The Company elected to account for forfeitures as they occur. The Company elected to recognize compensation expenses for awards to employees with only service conditions that have graded vesting schedules using the accelerated multiple option approach. n. Uncertain tax positions The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. If under the first step a tax position is assessed to be more likely than not of being sustained on audit, the second step is performed, under which the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. o. Deferred income taxes Deferred taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred taxes are expected to be paid or realized. The Company assesses realization of deferred income tax assets and, based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable. The Company may incur an additional tax liability in the event of intercompany dividend distributions by its subsidiaries. Such additional tax liability in respect of these foreign subsidiaries has not been provided for in these financial statements as it is the Company’s policy to permanently reinvest the subsidiaries’ earnings and to consider distributing dividends only in connection with a specific tax opportunity that may arise. Taxes that would apply in the event of disposal of investments in a foreign subsidiary have not been taken into account in computing the deferred taxes, as it is the Company’s intention to hold, and not to realize, these investments. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES p. Advertising Costs related to advertising and promotion of products are charged to sales and marketing expense as incurred. Advertising expenses were approximately $ 359,000 290,000 q. Net loss per share Basic and diluted net loss per share is computed by dividing the net loss for the period attributable to common stock by the weighted average number of shares of common stock outstanding during the period, including 0 11,696 2,741,355 2,840,179 r. Segment reporting The Company has one s. Fair value measurement The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. The Company has no financial instruments measured carried at fair value in each reporting period. The fair value of the Company’s financial instruments approximates their carrying values. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES t. Issued accounting pronouncements effective in future periods Financial Instruments - Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (“ASU 2019-10”). The purpose of this amendment is to create a two-tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (“SRCs”), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies had an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal periods beginning after December 15, 2022. Under the current SEC definitions, the Company meets the definition of an SRC and is adopting the deferral period for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company does not believe the adoption of this standard will have a material impact on its consolidated financial statements. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 3 - PROPERTY, PLANT AND EQUIPMENT a. Composition of assets, grouped by major classifications, is as follows: SCHEDULE OF PROPERTY PLANT AND EQUIPMENT 2022 2021 December 31, 2022 2021 ($ in thousands) Cost: Computer equipment $ 396 $ 361 Office furniture and equipment 231 157 Machinery and equipment 1,704 1,599 Leasehold improvements 494 243 Property plant and equipment, gross 2,825 2,360 Less - accumulated depreciation and amortization (1,908 ) (1,728 ) Net carrying amount $ 917 $ 632 b. Depreciation and amortization expenses totaled approximately $ 188,000 161,000

LIABILITY FOR EMPLOYEES RIGHT U

LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT	NOTE 4 - LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT Israeli labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. Pursuant to section 14 of the Israeli Severance Compensation Act, 1963, most of the Company’s employees are entitled to have monthly deposits, at a rate of 8.33 241,000 199,000 The severance pay liability of the Company for the rest of its Israeli employees, which reflects the undiscounted amount of the liability, is based upon the number of years of service and the latest monthly salary. The severance pay liability is partly covered by insurance policies and by regular deposits with recognized severance payment funds. The Company may only withdraw funds previously deposited for savings in connection with the payment of severance. The severance pay expenses for such employees were approximately $ 68,000 103,000 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

LEASE AGREEMENTS

LEASE AGREEMENTS	12 Months Ended
	Dec. 31, 2022
Lease Agreements
LEASE AGREEMENTS	NOTE 5 – LEASE AGREEMENTS 1) The Company’s Israeli subsidiary had a lease agreement for a facility in Israel, which expired on December 31, 2022 with an option to extend the agreement for two additional years until December 31, 2024. On May 25, 2022 the Company amended the agreement mentioned above and extended it until December 31, 2026 as well as leasing of additional space in the facility, the additional space amendment was taken in consideration when calculating the operating lease right of use assets and liabilities. 2) Operating lease cost for the years ended December 31, 2022 and 2021 was $ 442,000 476,000 Supplemental information related to leases are as follows: SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES December 31 December 31 2022 2021 ($ in thousands) ($ in thousands) Operating lease right-of-use assets 1,554 1,081 Current Operating lease liabilities (419 ) (420 ) Non-current operating lease liabilities (1,195 ) (781 ) Other information: Operating cash flows from operating leases (cash paid in thousands) (436 ) (437 ) Weighted Average Remaining Lease Term 4 3 Weighted Average Discount Rate 8.69 % 8.38 % Maturities of lease liabilities are as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES Amount ($ in thousands) 2023 432 2024 472 2025 472 2026 513 Total lease payments 1,889 Less imputed interest (275 ) Total 1,614 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

COMMITMENTS AND CONTINGENT LIAB

COMMITMENTS AND CONTINGENT LIABILITIES	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 6 - COMMITMENTS AND CONTINGENT LIABILITIES Distribution Agreement with Chinese Partner On February 3, 2021, the Company entered into a distribution agreement (the “Distribution Agreement”) with three China-based partners, pursuant to which the Chinese partners will be responsible for conducting the necessary registration trials for commercial approval of the Company’s products in China, followed by an eight-year exclusive distribution right to sell the Company’s products in China with the term of the agreement continuing on a year-to-year basis unless terminated. Under the Distribution Agreement, the China-based partners will be subject to minimum purchase obligations. The Distribution Agreement may be terminated for cause upon failure to meet minimum purchase obligations, failure to obtain regulatory approvals or for other material breaches. In addition, the agreement stipulates that if the Distributor fails to obtain the Regulatory Approvals by the time stipulated in the agreement due to the failure of the clinical trials, and this Agreement was terminated as a result of such failure to obtain Regulatory Approvals, InspireMD shall reimburse Distributor in an amount which is 50 1,000,000 50 See Note 7 for details regarding an investment transaction with one of the Chinese parties to the Distribution Agreement.

EQUITY

EQUITY	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
EQUITY	NOTE 7 - EQUITY a. Share capital The Company’s shares that previously traded on the NYSE American were approved for listing on the Nasdaq Capital Market (“Nasdaq”) and such shares began trading on Nasdaq on May 21, 2021 under the symbol, “NSPR.” On April 19, 2021, the Company filed with the Secretary of State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a one-for-fifteen reverse stock split of its common stock 0.0001 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 7 – EQUITY Public Offering On February 8, 2021, the Company closed an underwritten public offering (the “Offering”) of 1,935,484 units (“Units”), with each Unit being comprised of one share of the Company’s common stock, par value $ 0.0001 per share, and one Series G warrant (the “Series G Warrants”) to purchase one-half of one share of common stock. In connection with this public offering, the underwriter exercised its over-allotment option in full and purchased an additional 290,322 shares of common stock and 145,161 Series G Warrants. The offering price to the public was $ 9.30 per Unit. The Series G Warrants are immediately exercisable at a price of $ 10.23 per and expire five years from the date of issuance. The Company granted the underwriter compensation warrants to purchase up to 111,290 10.23 five years The net proceeds to the Company from the Offering, after giving effect to the exercise of the underwriter’s over-allotment option, were approximately $ 18.9 On February 3, 2021, the Company entered into a Distribution Agreement with three China-based partners, See Note 6b. for details about the Distribution Agreement. In addition, and on the same day, the Company entered into an investment transaction with one of the Chinese parties to the Distribution Agreement, which included a securities purchase agreement pursuant to which investor agreed to invest $ 900,000 89,445 10.062 During the year ended December 31, 2021, Series F and Series G warrants to purchase shares of common stock were exercised by investors at an exercise price of $ 7.425 10.23 1,225,412 9,469,000 ATM Offering During the year ended December 31, 2021, the Company sold 818,523 5,453,000 On July 7, 2016, the Company issued 442,424 17,303 207,528 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 7 – EQUITY On March 14, 2017, the Company issued 1,069,822 shares of Series C Preferred Stock in a public offering. During the year ended December 31, 2021, an amount of 625 831 1,718 2,284 4.815. As of December 31, 2022, the Company has outstanding warrants to purchase an aggregate of 1,793,815 SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK Number of Weighted Series E Warrants 198,159 $ 27.000 Series F Warrants 433,878 $ 7.425 Series G Warrants 1,092,344 $ 10.230 Underwriter Warrants 18,277 $ 7.425 Other warrants 51,157 $ 225.000 and above Total Warrants 1,793,815 $ As of December 31, 2022, the Company has 155,000,000 0.0001 150,000,000 5,000,000 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 7 – EQUITY b. Share-Based Compensation 1) Pursuant to the current Section 102 of the Israeli Tax Ordinance, which came into effect on January 1, 2003, options may be granted through a trustee (i.e., Approved 102 Options) or not through a trustee (i.e., Unapproved 102 Options). As a result of an election made by the Company under Section 102 of the Income Tax Ordinance, the Company will not be allowed to claim as an expense for tax purposes in Israel the amounts credited to the employee as capital gains to the grantees, although it will generally be entitled to do so in respect of the salary income component (if any) of such awards when the related tax is paid by the employee. 2) During the years ended December 31, 2022 and 2021, the Company granted stock options to the CEO, employees, consultants and directors to purchase a total of 154,508 225,225 2.61 2.97 3.89 10.05 360,356 1,026,000 154,508 109,839 three 44,669 3) During the years ended December 31, 2022 and 2021, the Company granted to the employees and directors 45,494 419,943 109,886 1,781,981 three-year 4) During the year ended December 31, 2021, the Company granted to the CEO 146,567 603,856 three INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 7 – EQUITY SCHEDULE OF STOCK OPTIONS GRANTED 5) The following table summarizes information about stock options granted to employees: Year ended December 31 2022 2021 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding - beginning of period 289,408 5.29 91,692 $ 6.20 Granted 7,841 2.61 205,223 4.90 Forfeited (2,537 ) 5.70 (7,507 ) 5.69 Outstanding- end of period 294,712 5.21 289,408 $ 5.29 Exercisable at the end of the period 123,115 5.51 28,360 6.26 6) The following table summarizes information about stock options granted to non-employees: Year ended December 31 2022 2021 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding - beginning of period 20,002 6.90 - - Granted 146,667 2.89 20,002 6.90 Forfeited - - - - Exercised - - - - Outstanding - end of period 166,669 3.37 20,002 6.90 Exercisable at the end of the period 35,667 3.61 - - 7) The following table summarizes information about restricted stock granted to employees: SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES Year ended December 31 2022 2021 Number of restricted stock Outstanding - beginning of period 527,668 185,725 Reverse Split Adjustments - 59 Granted 45,494 419,943 Forfeited (10,832 ) (20,822 ) Vested (206,379 ) (57,237 ) Outstanding - end of period 355,951 527,668 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 7 – EQUITY 8) The following table summarizes information about RSUs granted to employees: SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES Year ended December 31 2022 2021 Number of RSUs Outstanding - beginning of period 237,078 90,511 Granted - 146,567 Forfeited - - Vested - - Outstanding - end of period 237,078 237,078 9) The following table provides additional information about all options outstanding and exercisable: SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE Outstanding as of December 31, 2022 Exercise price Options Weighted average remaining contractual life (years) Options $ 2.61 2.97 154,508 9.25 29,000 $ 3.89 4.12 146,347 8.81 48,782 $ 4.95 10.05 156,473 8.00 78,298 $ 16.50 4,053 7.01 2,702 461,381 8.67 158,782 The weighted average of the remaining contractual life of total vested and exercisable options as of December 31, 2022 was 8.41 The aggregate intrinsic value of the total exercisable options as of December 31, 2022 was approximately $ 0 The weighted average fair value of options granted was $ 2.56 10) The following table sets forth the assumptions that were used in determining the fair value of options granted to employees for the year December 31, 2022 and 2021: SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES Year ended December 31 2022 2021 Expected life 5.125 6.5 5.5 6.5 Risk-free interest rates 1.79 2.88 0.59 1.40 Volatility 127.43 130.93 129.11 136.78 Dividend yield - - INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 7 – EQUITY The Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. Accordingly, as to ordinary course options granted, the expected term was determined using the simplified method, which takes into consideration the option’s contractual life and the vesting periods (for non-employees, the expected term is equal to the option’s contractual life). The annual risk-free rates are based on the yield rates of zero coupon non-index linked U.S. Federal Reserve treasury bonds as both the exercise price and the share price are in dollar terms. The Company’s expected volatility is derived from its historical data. 11) As of December 31, 2022, the total unrecognized compensation cost on employee and non-employee stock options, restricted stock and RSUs, related to unvested stock-based compensation, amounted to approximately $ 1.30 0.85 12) The following table summarizes the allocation of total share-based compensation expense in the consolidated statements of operations: SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE Year ended December 31 2022 2021 ($ in thousands) Cost of revenues $ 72 $ 49 Research and development 582 64 Sales and marketing 318 182 General and administrative 1,380 1,281 $ 2,352 $ 1,576 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

RELATED PARTIES TRANSACTIONS

RELATED PARTIES TRANSACTIONS	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTIES TRANSACTIONS	NOTE 8 – RELATED PARTIES TRANSACTIONS On May 10, 2021, the board of directors of the Company appointed a new member. During the twelve months ended December 31, 2022 and 2021, a consulting company whose founder and CEO is our new board member provided certain marketing services in the amount of $ 9,645 33,775

TAXES ON INCOME

TAXES ON INCOME	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
TAXES ON INCOME	NOTE 9 - TAXES ON INCOME a. Tax laws applicable to the Company and its subsidiaries Taxation in the United States InspireMD, Inc. is taxed under U.S. tax laws. Accordingly, the applicable federal corporate tax rate in 2022 is 21 Taxation in Israel InspiredMD, Ltd is taxed under Israeli tax laws. Accordingly, the applicable corporate tax rate in 2022 is 23 Taxation in Germany InspireMD GmbH is taxed according to the tax laws in Germany. Accordingly, the applicable tax rates are corporate tax rate of 15.825 17.15 b. Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the “Law”): InspireMD Ltd. has been granted a “Beneficiary Enterprises” status under the Investment Law including Amendment No. 60 thereof, which became effective in April 2005. The tax benefits derived from any such Beneficiary Enterprise relate only to taxable profits attributable to the specific program of investment to which the status was granted. The main benefit, to which InspireMD Ltd. is entitled, conditional upon the fulfilling of certain conditions stipulated by the above law, is a two-year exemption and five to eight years of a reduced tax rate of 10 23 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 9 - TAXES ON INCOME In the event of a distribution of tax-exempt income attributable to “Beneficiary Enterprises” as a cash dividend, the Company will be required to pay tax at a rate of 10% to 23% on the amount distributed, subject to certain conditions. In addition, dividends originating from income attributable to the “Beneficiary Enterprises” will be subject to a 20 Should InspireMD Ltd. derive income from sources other than the “Beneficiary Enterprises” during the period of benefits, such income shall be taxable at the regular corporate tax rate. 1) Conditions for entitlement to the benefits The entitlement to the above benefits is conditional upon InspireMD Ltd. fulfilling the conditions stipulated by the law, regulations published thereunder and the instruments of approval for the specific investments in approved assets. In the event of failure to comply with these conditions, the benefits may be cancelled, and InspireMD Ltd. may be required to refund the amount of the benefits, in whole or in part, with the addition of interest and linkage. The Company opted not to apply for Preferred Enterprise status (as defined in the Amendment of the Law for the Encouragement of Capital Investments, 1959). c. Carry forward tax losses As of December 31, 2022, the Company had a net carry forward tax loss of approximately $ 51 35 expires until 2037 16 80 Under the U.S. tax laws, for net operating losses (NOLs) arising after December 31, 2017, the Tax Cuts and Jobs Act enacted on December 22, 2017 (the “2017 Act”) limits a taxpayer’s ability to utilize NOL carryforwards to 80% of taxable income. In addition, NOLs arising after 2017 can be carried forward indefinitely, but carryback is generally prohibited. NOLs generated in tax years beginning before January 1, 2018, will not be subject to the foregoing taxable income limitation and will continue to have a two-year carryback and twenty-year carryforward period. As of December 31, 2022, InspireMD Ltd., an Israeli subsidiary, had a net carry forward tax loss of approximately $ 107 The Israeli subsidiary is taxed in the New Israeli Shekel (“NIS”), which is different from its functional currency (U.S. Dollar). The change in the Israeli subsidiary NOL’s for tax purposes is partly resulted by such rate differences. d. Loss before income taxes The components of loss before income taxes are as follows: SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES Year ended December 31 2022 2021 ($ in thousands) Loss before taxes on income: InspireMD, Inc. $ (4,773 ) $ (4,452 ) Subsidiaries (13,690 ) (10,421 ) $ (18,463 ) $ (14,873 ) INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 9 - TAXES ON INCOME e. Current taxes on income The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the change in valuation allowance in respect of tax benefits from carried forward tax losses due to uncertainty of the realization of such tax benefits. The changes in the valuation allowance for the year ended December 31, 2022 and 2021 were as follows: SCHEDULE OF CHANGES IN VALUATION ALLOWANCE Year ended December 31 2022 2021 ($ in thousands) Balance at the beginning of the year $ 39,212 $ 35,145 Changes during the year: Losses during the year (including foreign exchange rate effect) 859 4,067 Balance at the end of the year $ 40,071 $ 39,212 f. Accounting for Uncertain Tax position The following is a reconciliation of the total amounts of the Company’s uncertain tax positions during the year ended December 31, 2022 and 2021 were as follows: SCHEDULE OF RECONCILIATION OF UNCERTAIN TAX POSITIONS Year ended December 31, 2022 2021 ($ in thousands) Balance at beginning of period $ 89 $ 52 Increase in uncertain tax positions because of tax positions taken during the year 17 37 Balance at end of period $ 106 $ 89 A summary of open tax years by major jurisdiction is presented below: SCHEDULE OF OPEN TAX YEARS BY MAJOR JURISDICTION Jurisdiction Years U.S. 2019 2022 Israel 2018 2022 Germany 2019 2022 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 9 - TAXES ON INCOME SCHEDULE OF DEFERRED INCOME TAX g. Deferred income tax: 2022 2021 December 31, 2022 2021 ($ in thousands) Long-term: Provision for vacation and recreation pay 45 53 R&D expenses 1,452 1,000 Operating lease right of use assets (357 ) (248 ) Operating lease liabilities 371 276 Share-based compensation 3,021 2,849 Carry forward tax losses 35,507 35,248 Accrued severance pay, net 32 34 Deferred tax assets noncurrent 40,071 39,212 Less-valuation allowance (40,071 ) (39,212 ) Deferred tax assets - -

SUPPLEMENTARY FINANCIAL STATEME

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION	NOTE 10 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION Balance sheets: Inventory: SCHEDULE OF INVENTORIES 2022 2021 December 31, 2022 2021 ($ in thousands) Finished goods $ 179 $ 92 Work in process 510 436 Raw materials and supplies 932 615 Total inventory $ 1,621 $ 1,143 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 10 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER a. Accounts payable and accruals-other: 2022 2021 December 31, 2022 2021 ($ in thousands) Employees and employee institutions $ 1,853 $ 1,510 Accrued vacation and recreation pay 197 233 Accrued expenses 554 632 Clinical trial accrual 1,258 504 Current Operating lease liabilities 419 420 Other 130 155 Accounts Payable and Accruals - Other $ 4,411 $ 3,454

DISAGGREGATED REVENUE AND ENTIT

DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES	NOTE 11 – DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS Year ended December 31, 2022 2021 ($ in thousands) Germany $ 866 $ 948 Italy 970 981 Other 3,335 2,566 $ 5,171 $ 4,495 By product: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT Year ended December 31, 2022 2021 ($ in thousands) CGuard™ EPS $ 5,123 $ 4,309 MGuard Prime™ EPS 48 186 $ 5,171 $ 4,495 By principal customers: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS Year ended December 31, 2022 2021 Customer A 17 % 20 % Customer B 10 % 13 % All tangible long lived assets are located in Israel.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12 - SUBSEQUENT EVENTS Election to Receive Shares of Common Stock in lieu of Cash Compensation Beginning on January 1, 2023, non-employee directors may elect to receive all or a portion of their cash retainer amount in shares of the Company’s common stock under the 2021 Equity Incentive Plan. If a director makes that election, a stock award under the 2021 Equity Incentive Plan will be paid quarterly on the first day of each quarter (“Grant Dates”) and will become fully vested on the Grant Dates. The stock award will be determined by dividing (x) the product of the cash retainer amount and percentage of the cash retainer amount elected to be taken in shares by (y) the “Fair Market Value” (as defined in the 2021 Equity Incentive Plan) of a share on the Grant Dates. If a director’s service on the board terminates for any reasons prior to a Grant Date, he/she will receive a pro rata portion of shares or cash based on the number of days served on the board during the relevant quarter.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Use of estimates	a. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory valuations and assessing the likelihood of exercise of options to extend the lease term.
Functional currency	b. Functional currency The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). Accordingly, the functional currency of the Company and its subsidiaries is the U.S. dollar. The dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented in their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. The resulting translation gains or losses are recorded as financial income or expense, as appropriate. For transactions reflected in the statements of operations in foreign currencies, the exchange rates at transaction dates are used. Depreciation and changes in inventories and other changes deriving from non-monetary items are based on historical exchange rates.
Principles of consolidation	c. Principles of consolidation The consolidated financial statements include the accounts of the Company and of its subsidiaries. Intercompany transactions and balances have been eliminated upon consolidation.
Cash and cash equivalents	d. Cash and cash equivalents The Company considers all highly liquid investments, which include short-term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawal or use, to be cash equivalents. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES
Short-term bank deposits	e. Short-term bank deposits Bank deposits with original maturities of more than three months but less than one year are presented as part of short-term bank deposits. Deposits are presented at their cost which approximates market values including accrued interest. Interest on deposits is recorded as financial income.
Concentration of credit risk and allowance for doubtful accounts	f. Concentration of credit risk and allowance for doubtful accounts Financial instruments that may potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and short-term bank deposits, which are deposited in major financially sound institutions in the U.S, Israel and Germany, and trade accounts receivable. The Company’s trade accounts receivable is derived from revenues earned from customers from various countries. The Company performs ongoing credit evaluations of its customers’ financial condition and, requires no collateral from its customers. The Company also has a credit insurance policy for some of its customers. The Company maintains an allowance for doubtful accounts receivable based upon the expected ability to collect the accounts receivable. The Company reviews its allowance for doubtful accounts quarterly by assessing individual accounts receivable and all other balances based on historical collection experience and an economic risk assessment. If the Company determines that a specific customer is unable to meet its financial obligations to the Company, the Company provides an allowance for credit losses to reduce the receivable to the amount management reasonably believes will be collected, which is netted against “Accounts receivable - Trade”.
Inventory	g. Inventory Inventories are stated at the lower of cost (cost is determined on a “first-in, first-out” basis) or net realizable value. The Company’s inventories generally have a limited shelf life and are subject to impairment as they approach their expiration dates. The Company regularly evaluates the carrying value of its inventory and when, based on such evaluation, factors indicate that impairment has occurred, the Company impairs the inventories’ carrying value.
Leases	h. Leases Operating leases are included in operating lease right-of-use (“ROU”) assets. Short-term balances regarding lease liabilities are included in accounts payable and accruals - Other and long-term balances regarding lease liabilities are included in operating lease liabilities. ROU assets represent Company’s right to use an underlying asset for the lease term and lease liabilities represent obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses the incremental borrowing rate based on the information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The determination of the incremental borrowing rate requires management judgment based on information available at lease commencement. The lease terms may include periods covered by options to extend the lease when it is reasonably certain that the Company will exercise such options, and periods covered by options to terminate the lease when it is reasonably certain that the Company will not exercise such options. Operating lease cost is recognized on a straight-line basis over the lease term. Lease agreements that include lease and non-lease components are accounted for as a single lease component. The Company elected the short-term lease recognition exemption for leases with a lease term of 12 months or less.
Property, plant and equipment	i. Property, plant and equipment Property, plant and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets: over three years for computers and other electronic equipment, and seven to fifteen years for office furniture and equipment and machinery and equipment (mainly seven years ). Leasehold improvements are amortized on a straight-line basis over the term of the lease, which is shorter than the estimated life of the improvements.
Impairment in value of long-lived assets	j. Impairment in value of long-lived assets The Company tests long-lived tangible assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment would be recognized, and the assets would be written down to their estimated fair values, based on expected future discounted cash flows. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES
Revenue recognition	k. Revenue recognition A contract with a customer exists only when: 1) the parties to the contract have approved it and are committed to perform their respective obligations, 2) the Company can identify each party’s rights regarding the distinct goods or services to be transferred (“Performance Obligations”), 3) the Company can determine the transaction price for the goods or services to be transferred, 4) the contract has commercial substance and 5) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for Performance Obligations upon transfer of control to the customer, excluding sales taxes. Revenue from sales of goods, including sales to distributors, is recognized when the customer obtains control of the product, once the Company has a present right to payment and the customer has legal title, and risk and rewards of ownership are obtained by the customer. Generally, this occurs when products are shipped. In few cases when products are directly sold to medical centers on consignment basis, revenue is recognized when the product is consumed. The Company recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under selling and marketing expenses. Disaggregated revenue is disclosed in Note 11. The Company recognizes revenue net of value added tax (VAT).
Research and development costs	l. Research and development costs Research and development costs, including the costs of the Company’s US based clinical trial costs of approximately $4,468,000 2,037,000
Share-based compensation	m. Share-based compensation The Company has equity incentive plans under which the Company grants equity awards, including stock options, restricted stock and restricted stock units (“RSUs”) to employees and service providers. Employee equity awards are classified as equity awards and accounted for using the grant-date fair value method. The Company determines compensation expense associated with restricted stock and RSUs based on the fair value of our common stock on the date of grant. The fair value of option awards is estimated using the Black-Scholes valuation model and expensed over the requisite service period. The Company elected to account for forfeitures as they occur. The Company elected to recognize compensation expenses for awards to employees with only service conditions that have graded vesting schedules using the accelerated multiple option approach.
Uncertain tax positions	n. Uncertain tax positions The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. If under the first step a tax position is assessed to be more likely than not of being sustained on audit, the second step is performed, under which the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
Deferred income taxes	o. Deferred income taxes Deferred taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred taxes are expected to be paid or realized. The Company assesses realization of deferred income tax assets and, based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable. The Company may incur an additional tax liability in the event of intercompany dividend distributions by its subsidiaries. Such additional tax liability in respect of these foreign subsidiaries has not been provided for in these financial statements as it is the Company’s policy to permanently reinvest the subsidiaries’ earnings and to consider distributing dividends only in connection with a specific tax opportunity that may arise. Taxes that would apply in the event of disposal of investments in a foreign subsidiary have not been taken into account in computing the deferred taxes, as it is the Company’s intention to hold, and not to realize, these investments. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES
Advertising	p. Advertising Costs related to advertising and promotion of products are charged to sales and marketing expense as incurred. Advertising expenses were approximately $ 359,000 290,000
Net loss per share	q. Net loss per share Basic and diluted net loss per share is computed by dividing the net loss for the period attributable to common stock by the weighted average number of shares of common stock outstanding during the period, including 0 11,696 2,741,355 2,840,179
Segment reporting	r. Segment reporting The Company has one
Fair value measurement	s. Fair value measurement The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. The Company has no financial instruments measured carried at fair value in each reporting period. The fair value of the Company’s financial instruments approximates their carrying values. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES
Issued accounting pronouncements effective in future periods	t. Issued accounting pronouncements effective in future periods Financial Instruments - Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (“ASU 2019-10”). The purpose of this amendment is to create a two-tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (“SRCs”), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies had an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal periods beginning after December 15, 2022. Under the current SEC definitions, the Company meets the definition of an SRC and is adopting the deferral period for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company does not believe the adoption of this standard will have a material impact on its consolidated financial statements.

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT	SCHEDULE OF PROPERTY PLANT AND EQUIPMENT 2022 2021 December 31, 2022 2021 ($ in thousands) Cost: Computer equipment $ 396 $ 361 Office furniture and equipment 231 157 Machinery and equipment 1,704 1,599 Leasehold improvements 494 243 Property plant and equipment, gross 2,825 2,360 Less - accumulated depreciation and amortization (1,908 ) (1,728 ) Net carrying amount $ 917 $ 632

LEASE AGREEMENTS (Tables)

LEASE AGREEMENTS (Tables)	12 Months Ended
	Dec. 31, 2022
Lease Agreements
SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES	Supplemental information related to leases are as follows: SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES December 31 December 31 2022 2021 ($ in thousands) ($ in thousands) Operating lease right-of-use assets 1,554 1,081 Current Operating lease liabilities (419 ) (420 ) Non-current operating lease liabilities (1,195 ) (781 ) Other information: Operating cash flows from operating leases (cash paid in thousands) (436 ) (437 ) Weighted Average Remaining Lease Term 4 3 Weighted Average Discount Rate 8.69 % 8.38 %
SCHEDULE OF MATURITIES OF LEASE LIABILITIES	Maturities of lease liabilities are as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES Amount ($ in thousands) 2023 432 2024 472 2025 472 2026 513 Total lease payments 1,889 Less imputed interest (275 ) Total 1,614

EQUITY (Tables)

EQUITY (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK	SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK Number of Weighted Series E Warrants 198,159 $ 27.000 Series F Warrants 433,878 $ 7.425 Series G Warrants 1,092,344 $ 10.230 Underwriter Warrants 18,277 $ 7.425 Other warrants 51,157 $ 225.000 and above Total Warrants 1,793,815 $
SCHEDULE OF STOCK OPTIONS GRANTED	INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 7 – EQUITY SCHEDULE OF STOCK OPTIONS GRANTED 5) The following table summarizes information about stock options granted to employees: Year ended December 31 2022 2021 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding - beginning of period 289,408 5.29 91,692 $ 6.20 Granted 7,841 2.61 205,223 4.90 Forfeited (2,537 ) 5.70 (7,507 ) 5.69 Outstanding- end of period 294,712 5.21 289,408 $ 5.29 Exercisable at the end of the period 123,115 5.51 28,360 6.26 6) The following table summarizes information about stock options granted to non-employees: Year ended December 31 2022 2021 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding - beginning of period 20,002 6.90 - - Granted 146,667 2.89 20,002 6.90 Forfeited - - - - Exercised - - - - Outstanding - end of period 166,669 3.37 20,002 6.90 Exercisable at the end of the period 35,667 3.61 - -
SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES	SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES Year ended December 31 2022 2021 Number of restricted stock Outstanding - beginning of period 527,668 185,725 Reverse Split Adjustments - 59 Granted 45,494 419,943 Forfeited (10,832 ) (20,822 ) Vested (206,379 ) (57,237 ) Outstanding - end of period 355,951 527,668
SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES	SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES Year ended December 31 2022 2021 Number of RSUs Outstanding - beginning of period 237,078 90,511 Granted - 146,567 Forfeited - - Vested - - Outstanding - end of period 237,078 237,078
SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE	SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE Outstanding as of December 31, 2022 Exercise price Options Weighted average remaining contractual life (years) Options $ 2.61 2.97 154,508 9.25 29,000 $ 3.89 4.12 146,347 8.81 48,782 $ 4.95 10.05 156,473 8.00 78,298 $ 16.50 4,053 7.01 2,702 461,381 8.67 158,782
SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES	SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES Year ended December 31 2022 2021 Expected life 5.125 6.5 5.5 6.5 Risk-free interest rates 1.79 2.88 0.59 1.40 Volatility 127.43 130.93 129.11 136.78 Dividend yield - -
SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE	SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE Year ended December 31 2022 2021 ($ in thousands) Cost of revenues $ 72 $ 49 Research and development 582 64 Sales and marketing 318 182 General and administrative 1,380 1,281 $ 2,352 $ 1,576

TAXES ON INCOME (Tables)

TAXES ON INCOME (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES	The components of loss before income taxes are as follows: SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES Year ended December 31 2022 2021 ($ in thousands) Loss before taxes on income: InspireMD, Inc. $ (4,773 ) $ (4,452 ) Subsidiaries (13,690 ) (10,421 ) $ (18,463 ) $ (14,873 )
SCHEDULE OF CHANGES IN VALUATION ALLOWANCE	The changes in the valuation allowance for the year ended December 31, 2022 and 2021 were as follows: SCHEDULE OF CHANGES IN VALUATION ALLOWANCE Year ended December 31 2022 2021 ($ in thousands) Balance at the beginning of the year $ 39,212 $ 35,145 Changes during the year: Losses during the year (including foreign exchange rate effect) 859 4,067 Balance at the end of the year $ 40,071 $ 39,212
SCHEDULE OF RECONCILIATION OF UNCERTAIN TAX POSITIONS	The following is a reconciliation of the total amounts of the Company’s uncertain tax positions during the year ended December 31, 2022 and 2021 were as follows: SCHEDULE OF RECONCILIATION OF UNCERTAIN TAX POSITIONS Year ended December 31, 2022 2021 ($ in thousands) Balance at beginning of period $ 89 $ 52 Increase in uncertain tax positions because of tax positions taken during the year 17 37 Balance at end of period $ 106 $ 89
SCHEDULE OF OPEN TAX YEARS BY MAJOR JURISDICTION	A summary of open tax years by major jurisdiction is presented below: SCHEDULE OF OPEN TAX YEARS BY MAJOR JURISDICTION Jurisdiction Years U.S. 2019 2022 Israel 2018 2022 Germany 2019 2022
SCHEDULE OF DEFERRED INCOME TAX	SCHEDULE OF DEFERRED INCOME TAX g. Deferred income tax: 2022 2021 December 31, 2022 2021 ($ in thousands) Long-term: Provision for vacation and recreation pay 45 53 R&D expenses 1,452 1,000 Operating lease right of use assets (357 ) (248 ) Operating lease liabilities 371 276 Share-based compensation 3,021 2,849 Carry forward tax losses 35,507 35,248 Accrued severance pay, net 32 34 Deferred tax assets noncurrent 40,071 39,212 Less-valuation allowance (40,071 ) (39,212 ) Deferred tax assets - -

SUPPLEMENTARY FINANCIAL STATE_2

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SCHEDULE OF INVENTORIES	Inventory: SCHEDULE OF INVENTORIES 2022 2021 December 31, 2022 2021 ($ in thousands) Finished goods $ 179 $ 92 Work in process 510 436 Raw materials and supplies 932 615 Total inventory $ 1,621 $ 1,143
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER	SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER a. Accounts payable and accruals-other: 2022 2021 December 31, 2022 2021 ($ in thousands) Employees and employee institutions $ 1,853 $ 1,510 Accrued vacation and recreation pay 197 233 Accrued expenses 554 632 Clinical trial accrual 1,258 504 Current Operating lease liabilities 419 420 Other 130 155 Accounts Payable and Accruals - Other $ 4,411 $ 3,454

DISAGGREGATED REVENUE AND ENT_2

DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES (Tables)	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS	Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS Year ended December 31, 2022 2021 ($ in thousands) Germany $ 866 $ 948 Italy 970 981 Other 3,335 2,566 $ 5,171 $ 4,495
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT	By product: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT Year ended December 31, 2022 2021 ($ in thousands) CGuard™ EPS $ 5,123 $ 4,309 MGuard Prime™ EPS 48 186 $ 5,171 $ 4,495
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS	By principal customers: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS Year ended December 31, 2022 2021 Customer A 17 % 20 % Customer B 10 % 13 %

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	12 Months Ended
	Dec. 31, 2022 USD ($) segment shares	Dec. 31, 2021 USD ($) shares
Property, Plant and Equipment [Line Items]
Description of methodology used for computing depreciation	straight-line method
Research and development costs | $	$ 4,468,000	$ 2,037,000
Description of uncertain tax benefits	the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
Advertising expense | $	$ 359,000	$ 290,000
Number of operating segment | segment	1
Number of reportable segment | segment	1
Series B Preferred Stock [Member]
Property, Plant and Equipment [Line Items]
Weighted average shares of common stock issuable | shares	0	11,696
Series C Preferred Stock [Member]
Property, Plant and Equipment [Line Items]
Diluted loss per share | shares	2,741,355	2,840,179
Computers and Other Electronic Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Office Furniture and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years
Office Furniture and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	15 years
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years

SCHEDULE OF PROPERTY PLANT AND

SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 2,825	$ 2,360
Less - accumulated depreciation and amortization	(1,908)	(1,728)
Net carrying amount	917	632
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	396	361
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	231	157
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	1,704	1,599
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 494	$ 243

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation and amortization expenses	$ 188,000	$ 161,000

LIABILITY FOR EMPLOYEES RIGHT_2

LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]
Percentage of monthly deposits on salary	8.33%
Severance Type One [Member]
Restructuring Cost and Reserve [Line Items]
Severance expenses	$ 241,000	$ 199,000
Severance Type Two [Member]
Restructuring Cost and Reserve [Line Items]
Severance expenses	$ 68,000	$ 103,000

SCHEDULE OF SUPPLEMENTAL INFORM

SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Lease Agreements
Operating lease right-of-use assets	$ 1,554	$ 1,081
Current Operating lease liabilities	$ (419)	$ (420)
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Liabilities, Current	Liabilities, Current
Non-current operating lease liabilities	$ (1,195)	$ (781)
Operating cash flows from operating leases (cash paid in thousands)	$ (436)	$ (437)
Weighted Average Remaining Lease Term	4 years	3 years
Weighted Average Discount Rate	8.69%	8.38%

SCHEDULE OF MATURITIES OF LEASE

SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Lease Agreements
2023	$ 432
2024	472
2025	472
2026	513
Total lease payments	1,889
Less imputed interest	(275)
Total	$ 1,614

LEASE AGREEMENTS (Details Narra

LEASE AGREEMENTS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Lease Agreements
Operating lease expense	$ 442,000	$ 476,000

COMMITMENTS AND CONTINGENT LI_2

COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) - USD ($)	Feb. 03, 2021	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Distribution cost rate	50%	50%
Distribution reimbursement	$ 1,000,000

SCHEDULE OF ISSUANCE OF WARRANT

SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK (Details)	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Class of Stock [Line Items]
Total Warrants	1,793,815
Series E Warrants [Member]
Class of Stock [Line Items]
Total Warrants	198,159
Weighted average exercise price | $ / shares	$ 27
Series F Warrants [Member]
Class of Stock [Line Items]
Total Warrants	433,878
Weighted average exercise price | $ / shares	$ 7.425
Series G Warrants [Member]
Class of Stock [Line Items]
Total Warrants	1,092,344
Weighted average exercise price | $ / shares	$ 10.230
Underwriter Warrants [Member]
Class of Stock [Line Items]
Total Warrants	18,277
Weighted average exercise price | $ / shares	$ 7.425
Other Warrants [Member]
Class of Stock [Line Items]
Total Warrants	51,157
Weighted average exercise price, description	225.000 and above

SCHEDULE OF STOCK OPTIONS GRANT

SCHEDULE OF STOCK OPTIONS GRANTED (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Employee [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of options Outstanding - beginning of period	289,408	91,692
Weighted average exercise price Outstanding - beginning of period	$ 5.29	$ 6.20
Number of options Outstanding, Granted	7,841	205,223
Weighted average exercise price, Granted	$ 2.61	$ 4.90
Number of options Outstanding, Forfeited	(2,537)	(7,507)
Weighted average exercise price, Forfeited	$ 5.70	$ 5.69
Number of options Outstanding, Outstanding -end of period	294,712	289,408
Weighted average exercise price, Outstanding -end of period	$ 5.21	$ 5.29
Number of options Outstanding, Exercisable at the end of the period	123,115	28,360
Weighted average exercise price, Exercisable at the end of the period	$ 5.51	$ 6.26
Non-Employee [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of options Outstanding - beginning of period	20,002
Weighted average exercise price Outstanding - beginning of period	$ 6.90
Number of options Outstanding, Granted	146,667	20,002
Weighted average exercise price, Granted	$ 2.89	$ 6.90
Number of options Outstanding, Forfeited
Weighted average exercise price, Forfeited
Number of options Outstanding, Outstanding -end of period	166,669	20,002
Weighted average exercise price, Outstanding -end of period	$ 3.37	$ 6.90
Number of options Outstanding, Exercisable at the end of the period	35,667
Weighted average exercise price, Exercisable at the end of the period	$ 3.61
Number of options Outstanding, Exercised
Weighted average exercise price, Exercised

SCHEDULE OF RESTRICTED STOCK GR

SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES (Details) - Restricted Stock [Member] - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of restricted stock, Granted	45,494	419,943
Employee [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of restricted stock, Outstanding - beginning of period	527,668	185,725
Number of restricted stock, Reverse Split Adjustments		59
Number of restricted stock, Granted	45,494	419,943
Number of restricted stock, Forfeited	(10,832)	(20,822)
Number of restricted stock, Vested	(206,379)	(57,237)
Number of restricted stock, Outstanding - end of period	355,951	527,668

SCHEDULE OF RESTRICTED STOCK UN

SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES (Details) - Restricted Stock Units (RSUs) [Member] - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of restricted stock, Granted		146,567
Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of restricted stock, Outstanding - beginning of period	237,078	90,511
Number of restricted stock, Granted		146,567
Number of restricted stock, Forfeited
Number of restricted stock, Vested
Number of restricted stock, Outstanding - end of period	237,078	237,078

SCHEDULE OF ADDITIONAL INFORMAT

SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE (Details)	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 461,381
Weighted average remaining contractual life (years)	8 years 8 months 1 day
Options exercisable	158,782
Exercise Price One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price lower range | $ / shares	$ 2.61
Exercise price | $ / shares	$ 2.97
Options outstanding	154,508
Weighted average remaining contractual life (years)	9 years 3 months
Options exercisable	29,000
Exercise Price Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price lower range | $ / shares	$ 3.89
Exercise price | $ / shares	$ 4.12
Options outstanding	146,347
Weighted average remaining contractual life (years)	8 years 9 months 21 days
Options exercisable	48,782
Exercise Price Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price lower range | $ / shares	$ 4.95
Exercise price | $ / shares	$ 10.05
Options outstanding	156,473
Weighted average remaining contractual life (years)	8 years
Options exercisable	78,298
Exercise Price Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 16.50
Options outstanding	4,053
Weighted average remaining contractual life (years)	7 years 3 days
Options exercisable	2,702

SCHEDULE OF FAIR VALUE OF OPTIO

SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Risk-free interest rate, minimum	1.79%	0.59%
Risk-free interest rate, maximum	2.88%	1.40%
Volatility, minimum	127.43%	129.11%
Volatility, maximum	130.93%	136.78%
Dividend yield
Minimum [Member]
Expected life	5 years 1 month 15 days	5 years 6 months
Maximum [Member]
Expected life	6 years 6 months	6 years 6 months

SCHEDULE OF ALLOCATION OF TOTAL

SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Total share-based compensation expense	$ 2,352	$ 1,576
Cost of Sales [Member]
Total share-based compensation expense	72	49
Research and Development Expense [Member]
Total share-based compensation expense	582	64
Selling and Marketing Expense [Member]
Total share-based compensation expense	318	182
General and Administrative Expense [Member]
Total share-based compensation expense	$ 1,380	$ 1,281

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)						12 Months Ended
	Apr. 19, 2021	Feb. 08, 2021	Feb. 03, 2021	Mar. 14, 2017	Jul. 07, 2016	Dec. 31, 2022	Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]
Reverse stock split	one-for-fifteen reverse stock split of its common stock
Common stock, par value	$ 0.0001					$ 0.0001	$ 0.0001
Warrants to purchase common stock						1,793,815
Capital stock shares authorized						155,000,000
Capital stock par value						$ 0.0001
Common stock shares authorized						150,000,000	150,000,000
Stock option grants in period						154,508
Stock option description						154,508 options granted during the year ended December 31, 2022, 109,839 options are subject to a three-year vesting period, with one-third of such awards vesting each year and 44,669 options with performance conditions, mainly related to clinical activities.
Three Year Vesting Period [Member]
Subsidiary, Sale of Stock [Line Items]
Stock option grants in period						109,839
Performance Conditions [Member]
Subsidiary, Sale of Stock [Line Items]
Stock option grants in period						44,669
Share-Based Payment Arrangement, Option [Member]
Subsidiary, Sale of Stock [Line Items]
Stock option grants in period						154,508	225,225
Fair value of stock options						$ 360,356	$ 1,026,000
Vesting period						3 years
Share-Based Payment Arrangement, Option [Member] | Minimum [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise prices ranging						$ 2.61	$ 3.89
Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise prices ranging						$ 2.97	$ 10.05
Restricted Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Stock granted						45,494	419,943
Fair value of restricted shares						$ 109,886	$ 1,781,981
Stock vesting period						3 years
Weighted average of the remaining contractual life of vested and exercisable options						8 years 4 months 28 days
Aggregate intrinsic value of exercisable options						$ 0
Weighted average fair value of options granted						2.56
Restricted Stock Units (RSUs) [Member]
Subsidiary, Sale of Stock [Line Items]
Stock granted							146,567
Stock vesting period							3 years
Fair value of restricted stock units							$ 603,856
Employee and Non-employee Stock Options [Member]
Subsidiary, Sale of Stock [Line Items]
Unvested stock-based compensation						$ 1,300,000
Unvested stock-based compensation weighted-average period for recognition						10 months 6 days
Series B Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock convertible, shares							17,303
Converted preferred stock							207,528
Series C Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock outstanding						1,718	1,718
Preferred stock shares authorized						1,172,000	1,172,000
Securities Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of issuance of public offering			89,445
Shares Issued, Price Per Share			$ 10.062
Proceeds from sale of stock			$ 900,000
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of issuance of public offering							3,133,775
Preferred Stock Blank Check [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock shares authorized						5,000,000
Underwritten Public Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock, par value		$ 0.0001
Number of issuance of public offering		1,935,484
Shares Issued, Price Per Share		$ 9.30
Net proceeds from issuance of stock		$ 18,900,000
Underwritten Public Offering [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of issuance of public offering							1,225,412
Over allotment shares		290,322
Proceeds from sale of stock							$ 9,469,000
Underwritten Public Offering [Member] | Series G Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Over allotment shares		145,161
Shares Issued, Price Per Share		$ 10.23
Warrants and rights outstanding, term		5 years
Warrants exercise price							$ 10.23
Underwritten Public Offering [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants and rights outstanding, term		5 years
Warrants to purchase common stock		111,290
Warrants exercise price		$ 10.23
Underwritten Public Offering [Member] | Series F Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants exercise price							$ 7.425
At The Market Offering [Member] | Series B Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of issuance of public offering					442,424
At The Market Offering [Member] | Series C Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of issuance of public offering				1,069,822
Converted preferred stock						2,284	2,284
Preferred stock outstanding						1,718	1,718
At The Market Offering [Member] | Series C Convertible Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock convertible, shares							625
At The Market Offering [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of issuance of public offering							818,523
Net proceeds from issuance of stock							$ 5,453,000
Converted preferred stock							831
At The Market Offering [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding						1,793,815

RELATED PARTIES TRANSACTIONS (D

RELATED PARTIES TRANSACTIONS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
New Director [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Costs and expenses related party	$ 9,645	$ 33,775

SCHEDULE OF COMPONENTS OF LOSS

SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Loss before taxes on income	$ (18,463)	$ (14,873)
Parent Company [Member]
Loss before taxes on income	(4,773)	(4,452)
Subsidiaries [Member]
Loss before taxes on income	$ (13,690)	$ (10,421)

SCHEDULE OF CHANGES IN VALUATIO

SCHEDULE OF CHANGES IN VALUATION ALLOWANCE (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Balance at the beginning of the year	$ 39,212	$ 35,145
Changes during the year: Losses during the year (including foreign exchange rate effect)	859	4,067
Balance at the end of the year	$ 40,071	$ 39,212

SCHEDULE OF RECONCILIATION OF U

SCHEDULE OF RECONCILIATION OF UNCERTAIN TAX POSITIONS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Uncertain tax positions balance at beginning of period	$ 89	$ 52
Increase in uncertain tax positions because of tax positions taken during the year	17	37
Uncertain tax positions balance at end of period	$ 106	$ 89

SCHEDULE OF OPEN TAX YEARS BY M

SCHEDULE OF OPEN TAX YEARS BY MAJOR JURISDICTION (Details)	12 Months Ended
	Dec. 31, 2022
UNITED STATES | Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2019
UNITED STATES | Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2022
ISRAEL | Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2018
ISRAEL | Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2022
GERMANY | Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2019
GERMANY | Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2022

SCHEDULE OF DEFERRED INCOME TAX

SCHEDULE OF DEFERRED INCOME TAX (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Provision for vacation and recreation pay	$ 45	$ 53
R&D expenses	1,452	1,000
Operating lease right of use assets	(357)	(248)
Operating lease liabilities	371	276
Share-based compensation	3,021	2,849
Carry forward tax losses	35,507	35,248
Accrued severance pay, net	32	34
Deferred tax assets noncurrent	40,071	39,212
Less-valuation allowance	(40,071)	(39,212)	$ (35,145)
Deferred tax assets

TAXES ON INCOME (Details Narrat

TAXES ON INCOME (Details Narrative) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2020	Dec. 31, 2017
Operating Loss Carryforwards [Line Items]
Federal corporate tax rate	21%
Tax rate on income of beneficiary enterprises	20%
Net carry forward tax loss	$ 51		$ 35
Net loss carryforwards percentage	80%
Arising Before January One Two Thousand And Eighteen [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards expiration description		expires until 2037
Limited [Member]
Operating Loss Carryforwards [Line Items]
Net carry forward tax loss	$ 16
Israel Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Federal corporate tax rate	23%
Revised tax rate on income of preferred enterprises	10%
Tax rate on income of beneficiary enterprises	23%
Net carry forward tax loss	$ 107
Germany [Member]
Operating Loss Carryforwards [Line Items]
Federal corporate tax rate	15.825%
Corporate trade tax rate	17.15%

SCHEDULE OF INVENTORIES (Detail

SCHEDULE OF INVENTORIES (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Finished goods	$ 179	$ 92
Work in process	510	436
Raw materials and supplies	932	615
Total inventory	$ 1,621	$ 1,143

SCHEDULE OF ACCOUNTS PAYABLE AN

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Employees and employee institutions	$ 1,853	$ 1,510
Accrued vacation and recreation pay	197	233
Accrued expenses	554	632
Clinical trial accrual	1,258	504
Current Operating lease liabilities	419	420
Other	130	155
Accounts Payable and Accruals - Other	$ 4,411	$ 3,454

SCHEDULE OF REVENUES ATTRIBUTED

SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 5,171	$ 4,495
GERMANY
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	866	948
ITALY
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	970	981
Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 3,335	$ 2,566

SCHEDULE OF REVENUES ATTRIBUT_2

SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue from External Customer [Line Items]
Revenue	$ 5,171	$ 4,495
CGuard EPS [Member]
Revenue from External Customer [Line Items]
Revenue	5,123	4,309
MGuard Prime EPS [Member]
Revenue from External Customer [Line Items]
Revenue	$ 48	$ 186

SCHEDULE OF REVENUES ATTRIBUT_3

SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS (Details) - Sales [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Customer A [Member]
Revenue, Major Customer [Line Items]
Percentage of revenues per major customer	17%	20%
Customer B [Member]
Revenue, Major Customer [Line Items]
Percentage of revenues per major customer	10%	13%